When will the Smith & Nephew dividend start growing again?

The Smith & Nephew dividend yield has caught our writer’s eye as he considers adding the shares to his portfolio. But could it get higher in future?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Female Doctor In White Coat Having Meeting With Woman Patient In Office

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Medical devices manufacturer Smith & Nephew (LSE: SN) currently boasts a dividend yield of 3.2%. While that does not put it among the top ranks of FTSE 100 dividend payers, the yield is still attractive to me. But after previously rising most years for over a decade, the Smith & Nephew dividend has been static since the pandemic began. Might that change any time soon?

Flat interim dividend

In July, the company announced an interim dividend of 14.4c per share. On the one hand that was not surprising. After all, it was in line with Smith & Nephew’s stated policy of aiming to pay out an interim dividend equal to 40% of its most recent full-year dividend.

On the other hand, though, the news that the interim dividend would be the same for the fourth year in a row was a little disappointing. Prior to the pandemic, the company regularly raised its annual dividend. It rarely held its interim payout flat, while boosting the final one, meaning the overall annual amount rose. That last happened in 2017. Apart from that, it had raised its interim dividend every year this century before 2020. Since then, it has held both it and the final one flat.

Might the dividend rise this year?

That does not mean that this year’s full dividend will be flat. Although it did not increase the interim payout, the company could still choose to boost the final payout – just as it did back in 2017.

Will this happen? Nobody knows. After all, having held the dividend flat for the past few years, management could decide to do the same again. Such payouts are never guaranteed.

It is not that the company lacks money to increase it. In the first half, its earnings per share more than covered the payout.

Smith & Nephew did not give any specific indication of its intention for the full-year dividend in the interim results. But it did mention a capital allocation policy it adopted last year, including making reference to “our existing progressive dividend policy”.

A progressive dividend policy is one in which a company aims to raise its total payout each year. The results mentioning such a policy makes me think that the annual one may grow this year. That would happen if the company increases the size of its final payout.

My move

Whether that turns out to be the case will become clear when the company publishes its final results, probably in February.

I see Smith & Nephew as a blue-chip company with a quality business. Demand for the sorts of medical devices it produces will likely remain high. As quality matters for its customers, the company has pricing power. The Smith & Nephew dividend yield is attractive to me already. Any increase would only make it more so.

I do still see risks. Recovery from the pandemic has been slow, and inflation threatens to eat into profit margins. But I like the business and would consider buying the shares for my portfolio. If I do that now, hopefully I can benefit if the company starts increasing its annual dividend again.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

C Ruane has no position in any of the shares mentioned. The Motley Fool UK has recommended Smith & Nephew. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Here’s how I’m using a £20k ISA to target £11k+ in income 30 years from now

Is it realistic to put £20k in an ISA now and earn over half that amount every year in passive…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

If I could only keep 5 UK stocks from my portfolio I’d save these

Harvey Jones is running through his portfolio of top UK stocks to see which ones he couldn't bear to do…

Read more »

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

I’m aiming for a million buying unexciting shares!

By investing regularly in long-established, proven and even rather dull businesses, this writer plans to aim for a million. Here's…

Read more »

Investing Articles

3 things to consider before you start investing

Our writer draws on his stock market experience to consider a few vital lessons he would use to start investing…

Read more »

Investing Articles

Will this lesser-known £28bn growth stock be joining the FTSE 100 soon?

As the powers that be plan a reorganisation of Footsie listing rules, this massive under-the-radar growth stock could find its…

Read more »

Investing Articles

Fools wouldn’t touch these 5 FTSE 350 flops with a bargepole – how come I own 3 of them?

Harvey Jones took a chance on three struggling FTSE 350 stocks in the hope that they'd stage a dramatic recovery.…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

How I’m trying to make a million from passive income

Invest as much as possible, regularly, and use the passive income to plough back into more shares. Here's how millionaires…

Read more »

Investing Articles

I’d buy 30,434 shares of this UK dividend stock to target £175 a month in passive income

A top insider has spent over £1m buying this 9%-yielding passive income share over the last year. Roland Head explains…

Read more »